Crystalline forms of a kras g12c inhibitor

La presente invención se relaciona con formas cristalinas de un inhibidor de KRas G12C y sal de este. En particular, la presente invención se relaciona con formas cristalinas del inhibidor KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metoxi]-6,8-dihidro-5H-pirido[3,4-d]p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ANDREW, Samuel, GHARBAOUI, Tawfik, ANDRES, Patricia, CHEN, Cheng Yi, GANCEDO, Susana Del Rio, NELSON , Jennifer
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	ANDREW, Samuel GHARBAOUI, Tawfik ANDRES, Patricia CHEN, Cheng Yi GANCEDO, Susana Del Rio NELSON , Jennifer
description	La presente invención se relaciona con formas cristalinas de un inhibidor de KRas G12C y sal de este. En particular, la presente invención se relaciona con formas cristalinas del inhibidor KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metoxi]-6,8-dihidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2-fluoroprop-2-enoil)piperazin-2-il]acetonitrilo,composiciones farmacéuticas que comprenden las formas cristalinas, procesos para preparar las formas cristalinas y métodos de uso de estos. The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)- 4-[7-(8-chloro-l-naphthyI)-2-[[(2S)-l-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H- pyrido[3,4-d]pyrimidin-4-yI]-l-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof. The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CL2023000693A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CL2023000693A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CL2023000693A13</originalsourceid><addsrcrecordid>eNrjZNByLqosLknMycnMS1VIyy_KLVbIT1NIVMguSixWSDc0SlbIzMvITMosyS_iYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxzj5GBkbGBgYGZpbGjobGxKkCAIj_KRI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Crystalline forms of a kras g12c inhibitor</title><source>esp@cenet</source><creator>ANDREW, Samuel ; GHARBAOUI, Tawfik ; ANDRES, Patricia ; CHEN, Cheng Yi ; GANCEDO, Susana Del Rio ; NELSON , Jennifer</creator><creatorcontrib>ANDREW, Samuel ; GHARBAOUI, Tawfik ; ANDRES, Patricia ; CHEN, Cheng Yi ; GANCEDO, Susana Del Rio ; NELSON , Jennifer</creatorcontrib><description>La presente invención se relaciona con formas cristalinas de un inhibidor de KRas G12C y sal de este. En particular, la presente invención se relaciona con formas cristalinas del inhibidor KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metoxi]-6,8-dihidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2-fluoroprop-2-enoil)piperazin-2-il]acetonitrilo,composiciones farmacéuticas que comprenden las formas cristalinas, procesos para preparar las formas cristalinas y métodos de uso de estos. The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)- 4-[7-(8-chloro-l-naphthyI)-2-[[(2S)-l-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H- pyrido[3,4-d]pyrimidin-4-yI]-l-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof. The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.</description><language>eng ; spa</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231020&DB=EPODOC&CC=CL&NR=2023000693A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231020&DB=EPODOC&CC=CL&NR=2023000693A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ANDREW, Samuel</creatorcontrib><creatorcontrib>GHARBAOUI, Tawfik</creatorcontrib><creatorcontrib>ANDRES, Patricia</creatorcontrib><creatorcontrib>CHEN, Cheng Yi</creatorcontrib><creatorcontrib>GANCEDO, Susana Del Rio</creatorcontrib><creatorcontrib>NELSON , Jennifer</creatorcontrib><title>Crystalline forms of a kras g12c inhibitor</title><description>La presente invención se relaciona con formas cristalinas de un inhibidor de KRas G12C y sal de este. En particular, la presente invención se relaciona con formas cristalinas del inhibidor KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metoxi]-6,8-dihidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2-fluoroprop-2-enoil)piperazin-2-il]acetonitrilo,composiciones farmacéuticas que comprenden las formas cristalinas, procesos para preparar las formas cristalinas y métodos de uso de estos. The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)- 4-[7-(8-chloro-l-naphthyI)-2-[[(2S)-l-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H- pyrido[3,4-d]pyrimidin-4-yI]-l-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof. The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNByLqosLknMycnMS1VIyy_KLVbIT1NIVMguSixWSDc0SlbIzMvITMosyS_iYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxzj5GBkbGBgYGZpbGjobGxKkCAIj_KRI</recordid><startdate>20231020</startdate><enddate>20231020</enddate><creator>ANDREW, Samuel</creator><creator>GHARBAOUI, Tawfik</creator><creator>ANDRES, Patricia</creator><creator>CHEN, Cheng Yi</creator><creator>GANCEDO, Susana Del Rio</creator><creator>NELSON , Jennifer</creator><scope>EVB</scope></search><sort><creationdate>20231020</creationdate><title>Crystalline forms of a kras g12c inhibitor</title><author>ANDREW, Samuel ; GHARBAOUI, Tawfik ; ANDRES, Patricia ; CHEN, Cheng Yi ; GANCEDO, Susana Del Rio ; NELSON , Jennifer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CL2023000693A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ANDREW, Samuel</creatorcontrib><creatorcontrib>GHARBAOUI, Tawfik</creatorcontrib><creatorcontrib>ANDRES, Patricia</creatorcontrib><creatorcontrib>CHEN, Cheng Yi</creatorcontrib><creatorcontrib>GANCEDO, Susana Del Rio</creatorcontrib><creatorcontrib>NELSON , Jennifer</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ANDREW, Samuel</au><au>GHARBAOUI, Tawfik</au><au>ANDRES, Patricia</au><au>CHEN, Cheng Yi</au><au>GANCEDO, Susana Del Rio</au><au>NELSON , Jennifer</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Crystalline forms of a kras g12c inhibitor</title><date>2023-10-20</date><risdate>2023</risdate><abstract>La presente invención se relaciona con formas cristalinas de un inhibidor de KRas G12C y sal de este. En particular, la presente invención se relaciona con formas cristalinas del inhibidor KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metoxi]-6,8-dihidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2-fluoroprop-2-enoil)piperazin-2-il]acetonitrilo,composiciones farmacéuticas que comprenden las formas cristalinas, procesos para preparar las formas cristalinas y métodos de uso de estos. The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)- 4-[7-(8-chloro-l-naphthyI)-2-[[(2S)-l-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H- pyrido[3,4-d]pyrimidin-4-yI]-l-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof. The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; spa
recordid	cdi_epo_espacenet_CL2023000693A1
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	Crystalline forms of a kras g12c inhibitor
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A11%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ANDREW,%20Samuel&rft.date=2023-10-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECL2023000693A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true